SEC Tracker
Get the app

Aeglea BioTherapeutics SYRE

Aeglea BioTherapeutics: announces exit or restructuring costs, reports an executive or board change and discloses other events

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 99.1
Press release
  • Announces exit or restructuring costs (2.05)
  • Reports an executive or board change (5.02)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Aeglea BioTherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  2. Mannkind MNKD public float $1.1B, Jun 30, 2025
  3. Novavax NVAX public float $1.0B, Jun 30, 2025
  4. Harrow HROW public float $1.0B, Jun 30, 2025
  5. Aurinia Pharmaceuticals AUPH public float $1.0B, Jun 30, 2025